241 related articles for article (PubMed ID: 21917975)
21. Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant.
Guenaga J; Dosenovic P; Ofek G; Baker D; Schief WR; Kwong PD; Karlsson Hedestam GB; Wyatt RT
PLoS One; 2011 Jan; 6(1):e16074. PubMed ID: 21297864
[TBL] [Abstract][Full Text] [Related]
22. Recognition of membrane-bound fusion-peptide/MPER complexes by the HIV-1 neutralizing 2F5 antibody: implications for anti-2F5 immunogenicity.
Huarte N; Araujo A; Arranz R; Lorizate M; Quendler H; Kunert R; Valpuesta JM; Nieva JL
PLoS One; 2012; 7(12):e52740. PubMed ID: 23285173
[TBL] [Abstract][Full Text] [Related]
23. Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: effects of side-chain and backbone modifications and conformational constraints.
Tian Y; Ramesh CV; Ma X; Naqvi S; Patel T; Cenizal T; Tiscione M; Diaz K; Crea T; Arnold E; Arnold GF; Taylor JW
J Pept Res; 2002 Jun; 59(6):264-76. PubMed ID: 12010517
[TBL] [Abstract][Full Text] [Related]
24. The broadly neutralizing HIV-1 IgG 2F5 elicits gp41-specific antibody-dependent cell cytotoxicity in a FcγRI-dependent manner.
Tudor D; Bomsel M
AIDS; 2011 Mar; 25(6):751-9. PubMed ID: 21330910
[TBL] [Abstract][Full Text] [Related]
25. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.
Nelson JD; Brunel FM; Jensen R; Crooks ET; Cardoso RM; Wang M; Hessell A; Wilson IA; Binley JM; Dawson PE; Burton DR; Zwick MB
J Virol; 2007 Apr; 81(8):4033-43. PubMed ID: 17287272
[TBL] [Abstract][Full Text] [Related]
26. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.
Julien JP; Bryson S; Nieva JL; Pai EF
J Mol Biol; 2008 Dec; 384(2):377-92. PubMed ID: 18824005
[TBL] [Abstract][Full Text] [Related]
27. A gp41 MPER-specific llama VHH requires a hydrophobic CDR3 for neutralization but not for antigen recognition.
Lutje Hulsik D; Liu YY; Strokappe NM; Battella S; El Khattabi M; McCoy LE; Sabin C; Hinz A; Hock M; Macheboeuf P; Bonvin AM; Langedijk JP; Davis D; Forsman Quigley A; Aasa-Chapman MM; Seaman MS; Ramos A; Poignard P; Favier A; Simorre JP; Weiss RA; Verrips CT; Weissenhorn W; Rutten L
PLoS Pathog; 2013 Mar; 9(3):e1003202. PubMed ID: 23505368
[TBL] [Abstract][Full Text] [Related]
28. Human immunodeficiency virus type 1-neutralizing monoclonal antibody 2F5 is multispecific for sequences flanking the DKW core epitope.
Menendez A; Chow KC; Pan OC; Scott JK
J Mol Biol; 2004 Apr; 338(2):311-27. PubMed ID: 15066434
[TBL] [Abstract][Full Text] [Related]
29. Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems.
Veiga AS; Pattenden LK; Fletcher JM; Castanho MA; Aguilar MI
Chembiochem; 2009 Apr; 10(6):1032-44. PubMed ID: 19283693
[TBL] [Abstract][Full Text] [Related]
30. Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages.
Zhang R; Verkoczy L; Wiehe K; Munir Alam S; Nicely NI; Santra S; Bradley T; Pemble CW; Zhang J; Gao F; Montefiori DC; Bouton-Verville H; Kelsoe G; Larimore K; Greenberg PD; Parks R; Foulger A; Peel JN; Luo K; Lu X; Trama AM; Vandergrift N; Tomaras GD; Kepler TB; Moody MA; Liao HX; Haynes BF
Sci Transl Med; 2016 Apr; 8(336):336ra62. PubMed ID: 27122615
[TBL] [Abstract][Full Text] [Related]
31. Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines.
Ye L; Wen Z; Dong K; Wang X; Bu Z; Zhang H; Compans RW; Yang C
PLoS One; 2011; 6(5):e14813. PubMed ID: 21625584
[TBL] [Abstract][Full Text] [Related]
32. IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis.
Duchemin M; Khamassi M; Xu L; Tudor D; Bomsel M
Front Immunol; 2018; 9():244. PubMed ID: 29651286
[TBL] [Abstract][Full Text] [Related]
33. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.
Conley AJ; Kessler JA; Boots LJ; Tung JS; Arnold BA; Keller PM; Shaw AR; Emini EA
Proc Natl Acad Sci U S A; 1994 Apr; 91(8):3348-52. PubMed ID: 7512731
[TBL] [Abstract][Full Text] [Related]
34. Binding of HIV-1 gp41-directed neutralizing and non-neutralizing fragment antibody binding domain (Fab) and single chain variable fragment (ScFv) antibodies to the ectodomain of gp41 in the pre-hairpin and six-helix bundle conformations.
Louis JM; Aniana A; Lohith K; Sayer JM; Roche J; Bewley CA; Clore GM
PLoS One; 2014; 9(8):e104683. PubMed ID: 25105806
[TBL] [Abstract][Full Text] [Related]
35. Vaccination induces broadly neutralizing antibody precursors to HIV gp41.
Schiffner T; Phung I; Ray R; Irimia A; Tian M; Swanson O; Lee JH; Lee CD; Marina-Zárate E; Cho SY; Huang J; Ozorowski G; Skog PD; Serra AM; Rantalainen K; Allen JD; Baboo S; Rodriguez OL; Himansu S; Zhou J; Hurtado J; Flynn CT; McKenney K; Havenar-Daughton C; Saha S; Shields K; Schultze S; Smith ML; Liang CH; Toy L; Pecetta S; Lin YC; Willis JR; Sesterhenn F; Kulp DW; Hu X; Cottrell CA; Zhou X; Ruiz J; Wang X; Nair U; Kirsch KH; Cheng HL; Davis J; Kalyuzhniy O; Liguori A; Diedrich JK; Ngo JT; Lewis V; Phelps N; Tingle RD; Spencer S; Georgeson E; Adachi Y; Kubitz M; Eskandarzadeh S; Elsliger MA; Amara RR; Landais E; Briney B; Burton DR; Carnathan DG; Silvestri G; Watson CT; Yates JR; Paulson JC; Crispin M; Grigoryan G; Ward AB; Sok D; Alt FW; Wilson IA; Batista FD; Crotty S; Schief WR
Nat Immunol; 2024 Jun; 25(6):1073-1082. PubMed ID: 38816615
[TBL] [Abstract][Full Text] [Related]
36. Anti-HIV-1 antibodies 2F5 and 4E10 interact differently with lipids to bind their epitopes.
Franquelim HG; Chiantia S; Veiga AS; Santos NC; Schwille P; Castanho MA
AIDS; 2011 Feb; 25(4):419-28. PubMed ID: 21245727
[TBL] [Abstract][Full Text] [Related]
37. Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization.
Kim M; Sun ZY; Rand KD; Shi X; Song L; Cheng Y; Fahmy AF; Majumdar S; Ofek G; Yang Y; Kwong PD; Wang JH; Engen JR; Wagner G; Reinherz EL
Nat Struct Mol Biol; 2011 Oct; 18(11):1235-43. PubMed ID: 22002224
[TBL] [Abstract][Full Text] [Related]
38. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
Zwick MB; Jensen R; Church S; Wang M; Stiegler G; Kunert R; Katinger H; Burton DR
J Virol; 2005 Jan; 79(2):1252-61. PubMed ID: 15613352
[TBL] [Abstract][Full Text] [Related]
39. Antibody-Dependent Cellular Phagocytosis of HIV-1-Infected Cells Is Efficiently Triggered by IgA Targeting HIV-1 Envelope Subunit gp41.
Duchemin M; Tudor D; Cottignies-Calamarte A; Bomsel M
Front Immunol; 2020; 11():1141. PubMed ID: 32582208
[TBL] [Abstract][Full Text] [Related]
40. HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.
Chakrabarti BK; Pancera M; Phogat S; O'Dell S; McKee K; Guenaga J; Robinson J; Mascola J; Wyatt RT
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):877-87. PubMed ID: 21158699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
